CRISPR Therapeutics AG
CRSP
Rang in Aktien
#3549
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Aktienkurs
$50.26
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$4.86B
Veränderung (1 Tag)
0.43%
Veränderung (1 Jahr)
-30.51%
Land
CH
Handel CRISPR Therapeutics AG (CRSP)
Kategorie
Healthcare
Umsatz von CRISPR Therapeutics AG (CRSP)
Umsatz im Jun 2026 TTM: $13.39M
Laut den aktuellen Finanzberichten von CRISPR Therapeutics AG beträgt der derzeitige Umsatz des Unternehmens (TTM) $13.39M. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $35.00M ein Rückgang im Vergleich zu dem Umsatz im Jahr 2023, der $370.00M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für CRISPR Therapeutics AG von 2014 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $13.39M | 281.54% |
| 2025 | $3.51M | -89.97% |
| 2024 | $35.00M | -90.54% |
| 2023 | $370.00M | 84,762.39% |
| 2022 | $436.00K | -99.95% |
| 2021 | $913.08M | 126,893.18% |
| 2020 | $719.00K | -99.75% |
| 2019 | $289.59M | 9,169.85% |
| 2018 | $3.12M | -92.38% |
| 2017 | $41.00M | 693.90% |
| 2016 | $5.16M | 1,990.69% |
| 2015 | $247.00K | 0.00% |
| 2014 | 0.00 | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 94,167.47% |
US
|
|
| $2.23B | 16,536.80% |
US
|
|
| $15.74B | 117,465.17% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 44,861.82% |
NL
|
